Bowel Cancer Articles & Analysis
12 news found
The capital raise enables Carina to complete its Investigational New Drug (IND) enabling studies and initiate a CAR-T clinical trial of our LGR5 CAR-T cell for patients with advanced colorectal (bowel) cancer. “Colorectal cancer is Australia’s second deadliest cancer and its incidence is rising in people under the ...
Highlights Melbourne-based contract development and manufacturing organisation Cell Therapies will manufacture Carina Biotech’s LGR5 CAR-T cells for a first-in-human clinical trial for patients with advanced colorectal (bowel) cancer. Carina’s CAR-T cells are targeted at LGR5, a cancer stem cell marker that is highly expressed ...
Carina Biotech is very pleased to announce that we have submitted a pre-IND (Investigational New Drug) application to the US FDA (Food & Drug Administration) for our CAR-T therapy that targets a cancer stem cell antigen known as LGR5. This represents a major step towards taking our CAR-T cell (CNA3103) into a Phase I/IIa clinical trial in patients with advanced colorectal ...
Versius is being used to perform a range of high-volume general surgery and urological procedures, helping to treat patients with colorectal and urological cancers, bowel and kidney disease. High tech surgical care is highly prominent in the health system in Egypt, with adoption of the latest technology for RAS growing rapidly in Ministry of Health supported ...
Depending on its effectiveness in NSCLC, VTP-600 could be evaluated in other types of cancer in the future, including breast, bowel, bladder and melanoma. ...
Singapore-based CellVec will manufacture clinical-grade lentivirus – the first critical step in making LGR5 CAR-T cells for a first-in-human clinical trial for patients with advanced colorectal (bowel) cancer in late 2022. Lentiviruses are widely used as a tool to deliver genes of interest to cells. In this case, the lentivirus transduces (or inserts) a ...
The company’s clinical-stage pipeline includes product candidates being evaluated for the treatment of high-risk C. difficile infection, inflammatory bowel diseases, advanced or metastatic cancers, and food allergy. These investigational therapies are grounded in pioneering research – published in leading journals including Science, Nature, and Cell ...
The funding will enable us to undertake the required studies to initiate a clinical trial of our lead LGR5-targeted CAR-T program for the treatment of advanced colorectal (bowel) cancer in late 2022. Dr Steve Burnell, CEO of Minderoo Foundation’s Collaborate Against Cancer Initiative, commented: “We are pleased to accelerate the ...
Results further support the benign safety profile of VE202 and identify an optimal dosing regimen Vedanta plans to initiate a Phase 2 clinical trial of VE202 in ulcerative colitis patients in the second half of 2021 Vedanta Biosciences, a leading clinical-stage microbiome company developing a new category of oral therapies using defined bacterial consortia manufactured from clonal cell ...
Proximie has teamed up with Vodafone to pilot the role of 5G in increasing the connectivity and performance of remote assistance and training in cancer care. Trial with the assistance of 5G in using Proxime to ‘scrub in’ clinicians is taking place at University Hospital of Wales and University Hospital Llandough. Trial will be used in the diagnosis and treatment of ...
Edinburgh Molecular Imaging is part of an EPSRC funded consortium, led by Dr Jon Shephard of Heriot-Watt University in collaboration with Professor David Jayne from the University of Leeds to develop a revolutionary new bowel cancer surgery tool that will enable surgeons to carry out operations with far greater ...
(EM Imaging) has signed an exclusive global license for a novel optical imaging agent that could improve the detection of early-stage colorectal (bowel) cancer. EM Imaging, a company which develops and commercialises novel optical imaging agents, recently signed the licensing agreement with GE Healthcare Ltd. and Dyax Inc. EM Imaging will now complete the ...